PRECLINICAL SAFETY AND IMMUNOGENICITY OF CONTREVIR IN CHIMPANZEES

CONTREVIR 在黑猩猩中的临床前安全性和免疫原性

• 批准号: 8357711
• 负责人: Krishna K Murthy
• 金额: $ 20.83万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357711
• 关键词: AIDS/HIV problem; Biopsy Specimen; Blood; Blood Cell Count; Clinical Chemistry; Defective Viruses; Funding; Genes; Grant; HIV; HIV-1; Immune response; Immunotherapy; Infection; Monitor; National Center for Research Resources; Pan Genus; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Safety; Source; Time; United States National Institutes of Health; Virus; Virus Replication; cost; immunogenicity; lymph nodes; preclinical safety

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The primary objective of this study is to develop a safe and effective immunotherapy for HIV-1 infection.Therefore, two na¿ve chimpanzees will be inoculated with a gene deleted HIV-1 isolate designated as Contrevir which is non-disease causing but replication competent. Two HIV na¿ve chimpanzees will be intravenously inoculated with the defective virus , blood and lymph node biopsy samples will be collected at various time points to determine replication of the virus and immunological response of the host to the virus. In addition blood cell counts and clinical chemistry parameters will be monitored to determine safety aspects. It is anticipated that administration of Contrevir will be safe and will induce robust immune responses in chimpanzees. If Contrevir is safe and effective, it will add an immunotherapy approach to the treatment of HIV/AIDS

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 这项研究的主要目的是为HIV-1感染开发安全有效的免疫疗法。因此，将通过指定为contrevir的基因删除的HIV-1分离株接种两个Na¿Ve Imbanzees，该基因删除的HIV-1分离株是非疾病的，导致但复制能力。将在各个时间点收集两种艾滋病毒黑猩猩，以静脉内接种病毒，血液和淋巴结活检样品，以确定病毒的复制和宿主对病毒的免疫反应。另外，将监测血细胞计数和临床化学参数以确定安全方面。预计对Contrevir的给药将是安全的，并且会在黑猩猩中引起强大的免疫反应。如果Contrevir安全有效，它将为治疗艾滋病毒/艾滋病的治疗增加一种免疫疗法的方法